Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
The proposed amendments of the Pharmaceuticals and Medical Devices (PMD) Act, soon up for Diet deliberations, are intended to address regulatory and corporate governance issues that have been left unresolved over the past decade, a senior health ministry official says.…
To read the full story
Related Article
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- MHLW Preparing to Submit Bill to Amend PMD Act in Mid-February
January 17, 2025
- MHLW Publishes Panel Report on PMD Act Amendment
January 14, 2025
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
REGULATORY
- Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
- LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…